FGF23 and COVID-19: Another review suggested that timely use of recombinant human erythropoietin (EPO), EPO analogs, acetylsalicylic acid, bioactive lipids, or FGF23 antagonists in genetically predisposed adults with the angiotensin-converting enzyme (ACE) D allele may induce detrimental effects in COVID-19 patients.